Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Helicobacter pylori gastritis

3

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Potassium-transporting ATPase

2

Prostaglandin Synthesis and Regulation

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2022

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

Curative

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Takeda Pharmaceutical

2

Taisho Pharmaceutical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

MERCK INDEX

3

NCI_THESAURUS

3

PUBCHEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

VONOPRAZAN

1R5L3J156G

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 2022

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Potassium-transporting ATPase

Conditions:

Reflux esophagitis

Helicobacter pylori gastritis

Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively ...

inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.

SOFALCONE

2B668TJX8E

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin Synthesis and Regulation

Conditions:

Helicobacter pylori gastritis

Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. It is considered safe and effective for the treatment of gastritis and gastric ulcer. It is used in Japan. Adverse reactions are: liver dysfuncti...

on, jaundice, rash, constipation, dry mouth, heartburn.

Vonoprazan fumarate

4QW3X4AMLB

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 2022

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Potassium-transporting ATPase

Conditions:

Reflux esophagitis

Helicobacter pylori gastritis

Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively ...

inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1